A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis
This study evaluated the long-term safety and tolerability of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) triple combination (TC) treatment in participants with cystic fibrosis (CF).
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
St. Petersburg, Florida 33701, United States
Niles, Illinois 60714, United States
St Louis, Missouri 63110, United States
Buffalo, New York 14222, United States
Memphis, Tennessee 38103, United States
New Lambton, Australia
Newcastle upon Tyne, United Kingdom